Cardiff Oncology Inc
Company Profile
Business description
Cardiff Oncology Inc is a clinical-stage biotechnology company advancing cancer treatments focused on PLK1 inhibition, a validated oncology target with practice-changing potential. Its main asset, onvansertib, is a specific, oral PLK1 inhibitor currently being evaluated in a Phase 2 trial for first-line treatment of RAS-mutated metastatic colorectal cancer (mCRC), addressing a large, underserved patient population with high unmet need. Onvansertib is also under investigation in other PLK1-driven cancers through ongoing investigator-initiated trials and has shown robust single agent clinical activity in hard-to-treat tumors. By targeting tumor vulnerabilities, to overcome treatment resistance and deliver improved clinical outcomes for patients.
Contact
11055 Flintkote Avenue
San DiegoCA92121
USAT: +1 858 952-7570
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
31
Stocks News & Analysis
stocks
Big four bank holds up in weakening economic conditions
stocks
Our view after Coles’ shares plunge
stocks
Cheap ASX share remains overlooked by the market
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,013.20 | 36.00 | 0.40% |
| CAC 40 | 8,047.69 | 78.27 | 0.98% |
| DAX 40 | 25,981.09 | 162.88 | 0.63% |
| Dow JONES (US) | 51,983.98 | 213.67 | 0.41% |
| FTSE 100 | 10,761.33 | 31.55 | 0.29% |
| HKSE | 23,393.32 | 98.90 | 0.42% |
| NASDAQ | 25,164.31 | 272.68 | -1.07% |
| Nikkei 225 | 63,081.86 | 208.25 | -0.33% |
| NZX 50 Index | 13,678.09 | 20.54 | -0.15% |
| S&P 500 | 7,541.40 | 38.67 | -0.51% |
| S&P/ASX 200 | 8,891.00 | 34.50 | 0.39% |
| SSE Composite Index | 3,638.03 | 39.01 | 1.08% |